Cargando…

A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation

This phase I study was designed to examine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), the recommended dose (RD) for phase II, and the pharmacokinetics of NK105, a new polymeric micelle carrier system for paclitaxel (PTX). NK105 was administered as a 1-h intravenous infusi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamaguchi, T, Kato, K, Yasui, H, Morizane, C, Ikeda, M, Ueno, H, Muro, K, Yamada, Y, Okusaka, T, Shirao, K, Shimada, Y, Nakahama, H, Matsumura, Y
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360299/ https://www.ncbi.nlm.nih.gov/pubmed/17595665 http://dx.doi.org/10.1038/sj.bjc.6603855

Ejemplares similares

NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
por: Hamaguchi, T, et al.
Publicado: (2005)

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel
por: Negishi, T, et al.
Publicado: (2006)

Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
por: Matsumura, Y, et al.
Publicado: (2004)

An in vivo mechanism for the reduced peripheral neurotoxicity of NK105: a paclitaxel-incorporating polymeric micellar nanoparticle formulation
por: Nakamura, Iwao, et al.
Publicado: (2017)

Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
por: Yamada, Y, et al.
Publicado: (2003)

Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors
por: Mukai, Hirofumi, et al.
Publicado: (2016)

Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil)
por: Tsukioka, Yoshihisa, et al.
Publicado: (2002)

Phase II study of S-1 in patients with advanced biliary tract cancer
por: Ueno, H, et al.
Publicado: (2004)

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer
por: Okusaka, T, et al.
Publicado: (2004)

A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer
por: Ikeda, M, et al.
Publicado: (2007)

A Chitosan-Based Micellar System as Nanocarrier For the Delivery of Paclitaxel
por: Han, Yang, et al.
Publicado: (2020)

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer
por: Matsubara, J, et al.
Publicado: (2008)

Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer
por: Kosaka, Yoshimasa, et al.
Publicado: (2022)

Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma
por: Kondo, S, et al.
Publicado: (2013)

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma
por: Shiba, Satoshi, et al.
Publicado: (2012)

Combined Delivery of Paclitaxel and Tanespimycin via Micellar Nanocarriers: Pharmacokinetics, Efficacy and Metabolomic Analysis
por: Katragadda, Usha, et al.
Publicado: (2013)

Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients
por: Ueno, H, et al.
Publicado: (2009)

Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients
por: Borgå, Olof, et al.
Publicado: (2019)

A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer
por: Ikeda, M, et al.
Publicado: (2002)

ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer
por: Watanabe, T, et al.
Publicado: (2015)

Colloidal dispersions and micellar behavior
por: Mittal, K L
Publicado: (1975)

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma(†)
por: Al-Batran, S.-E., et al.
Publicado: (2016)

El Artículo 105 constitucional /
por: Castro y Castro, Juventino V.
Publicado: (2004)

A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
por: Fujiwara, Yasuhiro, et al.
Publicado: (2019)

Kre28–Spc105 interaction is essential for Spc105 loading at the kinetochore
por: Roy, Babhrubahan, et al.
Publicado: (2022)

Biodistribution and pharmacokinetics of a telodendrimer micellar paclitaxel nanoformulation in a mouse xenograft model of ovarian cancer
por: Xiao, Wenwu, et al.
Publicado: (2012)

A pH-Sensitive Polymeric Micellar System Based on Chitosan Derivative for Efficient Delivery of Paclitaxel
por: Han, Yang, et al.
Publicado: (2021)

Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery
por: Lu, Jun, et al.
Publicado: (2023)

A Micellar Formulation of Quercetin Prevents Cisplatin Nephrotoxicity
por: Casanova, Alfredo G., et al.
Publicado: (2021)

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
por: Yamada, Y, et al.
Publicado: (2008)

Pharmacokinetic Evaluation of a DSPE-PEG(2000) Micellar Formulation of Ridaforolimus in Rat
por: Remsberg, Connie M., et al.
Publicado: (2012)

Study of the largest multiwavelength campaign of microquasar GRS 1915+105
por: Ueda, Y, et al.
Publicado: (2002)

A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer(†)
por: Ueno, M., et al.
Publicado: (2016)

The Gamow-Teller decay of $^{105}$Sn to three-particle states in $^{105}$In
por: Pfützner, M, et al.
Publicado: (1994)

Comparison of the Micellar Incorporation and the Intestinal Cell Uptake of Cholecalciferol, 25-Hydroxycholecalciferol and 1-α-Hydroxycholecalciferol
por: Desmarchelier, Charles, et al.
Publicado: (2017)

Incorporating physiologically relevant mobile phases in micellar liquid chromatography for the prediction of human intestinal absorption
por: Shokry, Dina S., et al.
Publicado: (2018)

Supramolecular micellar nanoaggregates based on a novel chitosan/vitamin E succinate copolymer for paclitaxel selective delivery
por: Lian, He, et al.
Publicado: (2011)

A Mixed Micellar Formulation for the Transdermal Delivery of an Indirubin Analog
por: Seo, Seol Hwa, et al.
Publicado: (2020)

Light-Responsive Polymeric Micellar Nanoparticles with Enhanced Formulation Stability
por: Kim, Kyoung Nan, et al.
Publicado: (2021)

Enabling In Vivo Optical Imaging of an Osmium Photosensitizer by Micellar Formulation
por: Shah, Drashti, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_24m2v22o7k57on0ldo36u141dk